Facilitated By

San Antonio Medical Foundation

Combined Phase 3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating The Efficacy And Safety Of Filgotinib In The Induction And Maintenance Of Remission In Subjects With Moderately To Severely Active Crohns Disease

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
GENEVA
Research Start Date
Status
Active

The Study is combined Phase 3 double-blind, randomized, placebo-controlled studies to evaluate the efficacy and safety of filgotinib in the induction and maintenance of remission in subjects with moderately to severely active CD.

Clinical Care
Infectious Disease
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.